H<sub>2</sub>S-Activable BiFeO<sub>3-<i>x</i></sub> Nanocatalysts for Ferroptosis-Driven Cancer Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41622764.
- Also identified by DOI 10.1021/acsnano.5c18008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Controlling ferroptosis through material redox dynamics represents a frontier in the field of catalytic nanomedicine. Here, we introduce nonstoichiometric bismuth ferrite (BiFeO<sub>3-<i>x</i></sub>) as an H<sub>2</sub>S-activable semiconductor that couples oxygen-vacancy-enabled charge modulation with endogenous sulfur chemistry to achieve spatiotemporally controlled immunogenic ferroptosis. Upon exposure to tumor-enriched gasotransmitter H<sub>2</sub>S, BiFeO<sub>3-<i>x</i></sub> undergoes a transformation into Bi<sub>2</sub>S<sub>3</sub> while releasing Fe<sup>2+</sup> ions to trigger Fenton-like lipid peroxidation. The material's mixed-valence Fe redox pair amplifies reactive oxygen species generation under 808 nm excitation, coupling photothermal energy dissipation with catalytic ferroptotic stress. Biologically, this multiresponse process initiates mitochondrial collapse, glutathione peroxidase 4 depletion, and lipid peroxide accumulation, driving apoptosis-ferroptosis cascades. <i>In vivo</i>, photoacoustic-guided therapy and mass cytometry profiling reveal profound immune remodeling, such as dendritic cell maturation, CD8<sup>+</sup> T cell infiltration, and M1 macrophage polarization, implying the conversion of "cold" colorectal tumors into immunogenic tumor microenvironments. This work establishes a defect-chemistry-oriented design framework for engineering redox-programmable nano semiconductors that translate lattice instability into biological selectivity, bridging ferroelectric materials science and immune oncology.
Medical subject headings
- Ferroptosis
- Bismuth
- Immunotherapy
- Ferric Compounds
- Neoplasms